OKYO Pharma Limited Prices $5.3 Million Offering of ADSs

LONDON, March 13, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq:OKYO, LSE:OKYO) (“OKYO Pharma” or the “Company“), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases (“DED”) and ocular pain, announced the pricing of a reasonable best efforts public offering of 3,503,665 American Depositary Shares (the “ADSs”) at a public offering price of $1.50 per ADS. The gross proceeds to the Company from this offering are expected to be approximately $5.3 million before deducting offering expenses. The offering is expected to close on March 15, 2023, subject to customary closing conditions.

Read more at globenewswire.com